Thanks for this information! I've been researching various liquid biopsy alternatives for AS patients and I had not seen this one. Apparently, Trinity Biotech bought the start-up company who invented the Epicapture Test in October 2024 and has announced plans to commercialize in the US...however, no date has been set....

Read where this particular test only has 5% false positives....that's amazing when one considers that the false positives for the standard PSA blood test is 46.6%, according to a 2022 study….imagine if a company were attempting to bring such a test to market in 2025....that type of test wouldn't even make it to first base after an initial screening of possible solutions.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9818944/
In 2021, ~60% of low risk PCa men have chosen AS, as compared to only ~26% in 2014. This means that the market for a noninvasive biopsy method has grown exponentially; therefore, I believe it's just a matter of time (sooner rather than later) that such a liquid biopsy replacement test will be made available...there is a large and growing market and we all know what the means for the medical industry....